<DOC>
	<DOCNO>NCT00618384</DOCNO>
	<brief_summary>For patient advanced HCC suitable resection liver transplantation without extrahepatic manifestation , local therapy TACE regard standard treatment . The present study plan evaluate combination TACE sorafenib . A combination TACE multitarget inhibitor like sorafenib may improve outcome patient HCC .</brief_summary>
	<brief_title>TACE Sorafenib Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>histologically confirm HCC suitable resection liver transplantation Patients measurable disease accord RECIST Performance status ECOG 02 Normal organ bone marrow function ( define ) Women childbearing potential must perform negative serum pregnancy test male female patient must use approved contraceptive method treatment 3 month end treatment end treatment study medication Written inform consent Patient eligible liver resection liver transplantation Extrahepatic tumor manifestation Thrombosis portal vein &gt; 8 point accord Child Pugh classification Prior TACE RFTA local ablative treatment Prior systemic anticancer chemotherapy radiotherapy HCC Total bilirubin &gt; 4.5 mg/dl Life expectancy le 12 week Esophageal varix grade III without prophylactic band ligation Cardiac disease ( define ) Uncontrolled hypertension Known suspect hyperthyroid state Known brain metastasis Patients seizure disorder require medication History organ allograft Active clinically serious infection &gt; CTCAE grade 2 Thrombotic embolic event Hemorrhage/bleeding event ( define ) Acute variceal bleed Therapeutic anticoagulation vitamin K antagonist ( define ) Known suspect allergy sorafenib , doxorubicin lipiodol agent give course trial Contraindications use sorafenib , doxorubicin lipiodol Previous cancer distinct primary site histology HCC ( define ) substance abuse Participation another clinical trial investigational study drug Lactating woman Incapability give valid inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>TACE</keyword>
	<keyword>hepatocellular carcinoma</keyword>
</DOC>